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cense.Abstract Purpose: The purpose of our study was to assess the value of functional magnetic res-
onance spectroscopy (1H MRS) in evaluating patients with recurrent cancer breast after breast con-
servative therapy (BCT) and radiation therapy by the presence of the choline-containing
compounds (Cho) as a marker of malignancy.
Patients and methods: Twenty-six patients were included in the study all the patients were subjected
to previous BCT and associated radiation therapy. All of them were suspected to have tumor recur-
rence by clinical examinations, periodic mammographic examination and or ultrasonography. All
the patients were submitted to dynamic contrast enhanced magnetic resonance imaging (DCE-
MRI) followed by magnetic resonance spectroscopy (MRS) at 1.5 T MRI machine.
Results: Local recurrence was conﬁrmed by histopathology in 19 patients, MRS detected 18
patients with sensitivity of 94.7%, false positive was seen in one patient in whom histopathology
revealed inﬂammatory mastitis (speciﬁcity 85.7%). One patient was false negative diagnosed by his-
topathology as ductal carcinoma in situ (DCIS) with negative predictive value of 85.7% and overall
accuracy of 92.3%.partment, Zagazig University
com (E.M. Khattab).
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20 E.M. Khattab et al.Conclusion: In our study breast MRS using choline (Cho) integral was accurate in evaluating
patients with recurrent breast masses after BCT and radiation therapy. It reaches a high level of
diagnostic performance.
 2011 Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
1H MRS has become an adjacent to dynamic contrast en-
hanced MRI (DCE-MRI) in the clinical evaluation of breast
lesions. Malignant lesions are more likely to show high levels
of choline-containing compounds compared to benign or nor-
mal breast tissues, and this observation may serve as the basis
for differentiating between malignant and benign breast Le-
sions (1). Choline-containing compounds are the major com-
ponents of cell membrane required for structural stability
and cell proliferation (2). Many studies have shown that Cho
peak is elevated in neoplastic tissues. The increased Cho in
neoplastic tissues may be due to increased membrane turnover
by replicating cells (1). At 1H MRS the choline-containing
metabolites resonates at 3.2 ppm (more speciﬁcally, between
3.14 and 3.34 ppm) that contribute to the total choline-con-
taining (tCho) peak (3). The underlying mechanisms for the
elevated level of choline-containing compounds in breast can-
cer have been extensively investigated. Since choline level rep-
resents a proliferative marker, many biological factors may
affect its concentration within the tumor (1).
It has been reported that the degree of elevated choline-con-
taining compounds is related to the grade of the tumor, with
higher levels in high-grade than in low-grade lesions (4,5).
The relationship between the presence of choline-containing
compounds and other commonly analyzed breast cancer bio-
markers, such as estrogen receptor, progesterone receptor
and human epidermal growth factor receptor 2 (HER-2 recep-
tor), was less studied (6).
Aim of this study is to evaluate the role of 1H MRS in
detecting cancer recurrence in patients after conservative surgi-
cal treatment and local radiation therapy.2. Patients and methods
In this study 26 female patients were examined in the period
between July 2010 and May 2011 at Zagazig University hospi-
tals. All the patients underwent conservative surgical treatment
of breast cancer. All the patients were suspected to have either
tumor recurrence or post operative complications at the site of
the surgery at least 6 months after the end of radiation ther-
apy. They all underwent a breast evaluation, performed by
the breast radiologist with mammography, associated with
an ultrasound examination. Recurrence was suspected either
by ultrasound or by mammography, or by both examinations.
When a malignant lesion was suspected (by ultrasound and/or
mammographic Breast Imaging Reporting and Data System
BIRADS IV or V), the patient underwent a contrast enhanced
breast magnetic resonance mammography (MRM) and mag-
netic resonance spectroscopy (MRS). All the patients under-
went ﬁne needle aspiration biopsy (FNAB), core biopsy or
excisional biopsy and histopathological reports were corre-
lated with our data. The sensitivity, speciﬁcity, accuracy, posi-tive and negative predictive values of 1H MRS in detection of
recurrent disease or post surgical/post radiation therapy se-
quels were calculated
2.1. Examination technique
The MRI study was performed using a 1.5-T whole-body MR
imaging and spectroscopic system (MR achieva) Philips medi-
cal systems using a bilateral standard phased array breast coil.
The imaging protocol consisted of high-resolution precontrast
T1 and T2 weighted images, bilateral DCE-MRI, and MRS.
Examinations were done in axial, sagittal and coronal se-
quences, precontrast T1-weighted images were acquired using
a spin-echo pulse sequence Fast Spin Echo T2-weighted imag-
ing with fat suppression (TR/TE 100/4000–6000); the ﬁeld of
view was adjusted to cover the breast (260–320 mm) with slice
thickness of 4 mm, and an acquisition matrix of 256 · 192,
FVO of 35 and number of excitations 2. A three dimensional
(3D) bilateral dynamic images were obtained.
2.2. 1H MRS protocol and analysis
After completing the DCE-MRI, the acquisition of MR spec-
trum was performed using the localized single-voxel technique
with the point-resolved spectroscopic sequence (PRESS). The
spectroscopic voxel was placed on the post injection subtrac-
tion images. The voxel size ranged from 4.2 to 8.0 cm3. It
was carefully positioned to cover the enhanced lesion on the
subtraction images and avoid contaminations with the sur-
rounding tissues. The water suppression was performed by
using a point-resolved spectroscopy or PRESS with three pulse
chemical shift selective CHESS. The fat signal was indepen-
dently attenuated by using frequency selective lipid suppres-
sion technique. The PRESS acquisition sequence parameters
were as follows: TR/TE = 1200/270; ﬂip angle, 90; 512 mea-
surements. The sequence acquisition time was 12 min. This rel-
atively long TE (270 ms) was chosen to increase the visibility of
the Cho resonance because of the longer T2 of Cho in compar-
ison with that of lipids (3). The absolute Cho levels were quan-
tiﬁed by using a Gaussian line-shape ﬁtting model and the
unsuppressed water signal was used as an internal reference
(7).
3. Results
Twenty-six patients with recurrent breast masses following sur-
gical treatment and radiation therapy were included in this
study, four patients underwent lumpectomy alone, 10 patients
underwent lumpectomy with axillary dissection and 12 patients
underwent quadrectomy with axillary dissection. Their ages
ranged from 31 to 68 years with mean age 48.5 years. All our
patients were subjected to conventional mammography, ultra-
sonography and dynamic contrast enhanced MRI (DCE-MRI)
Table 3 Sensitivity, speciﬁcity and accuracy of the diagnostic
tests.
Mammography Ultrasonography MRS
Sensitivity (%) 47.3 78.9 94.7
Speciﬁcity (%) 28.2 57.1 85.7
Accuracy (%) 42.3 73 92.3
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underwent core biopsy guided by ultrasonography, two pa-
tients underwent FNAB guided by ultrasonography and the
remaining seven patients were subjected to excisional biopsy.
Of the 26 patients 19 were diagnosed by histopathology as
recurrent breast cancer. Out of the 19 patients 14 were diag-
nosed as inﬁltrating ductal carcinoma (IDC) not otherwise
speciﬁed; two as invasive lobular carcinoma; two as medullary
carcinoma; and one as ductal carcinoma in situ (DCIS). Out of
the seven negative patients, four patients showed post radia-
tion fat necrosis, two patients showed post operative ﬁbrosis
and one patient showed focal area of mastitis.
Nineteen patients were positive for recurrent breast cancer
by MR spectroscopy. All the patients were positive for choline,
only one is false positive and was diagnosed by histopathology
as focal mastitis. Four patients showed criteria of associated
malignant axillary lymph nodes in the MRS examination with
positive choline detection. All of these lymph nodes were posi-
tive in histopathological study.
Of the seven negative patients, true negative were six and
false negative was one patient diagnosed histopathologically
as DCIS (choline could not be detected within the breast mass)
with sensitivity of 94.7%, speciﬁcity of 85.7% and accuracy of
92.3%, positive predictive value 94.7% and negative predictive
value 85.7%.
By conventional mammography 14 patients were suspected
to have tumor recurrence, nine were true positive, ﬁve were
false positive, two were true negative and ten were false nega-
tive (six out of ten patients showed dense breast) with sensitiv-
ity 47.3%, speciﬁcity 28.2% and accuracy 42.3%, positive
predictive value 64.2% and negative predictive value 16.6%
while ultrasonography was suspected in seventeen patients
with recurrent breast cancer. Fifteen patients were true posi-
tive, three were false positive, four were true negative and four
were false negative with sensitivity of 78.9%, speciﬁcity 57.1%,
accuracy 73%, positive predictive value 83.3% and negative
predictive value 50% (Tables 1–3 and Figs. 1–5).
4. Discussion
Breast conservative therapy (BCT) has become an established
treatment modality in early breast cancers with long term sur-
vival equal to that with more radical surgery. However local
recurrence remains a problem, by combination between BCT
and radiation therapy the incidence reduced to 1–2% per year
(8).Table 1 Histopathological results of our study group.
Positive for tumor recurrence (n= 19) 73% IDC (n= 14), invasive lob
Negative for tumor recurrence (n= 7) 27% Post radiation necrosis (n=
Table 2 Statistical analysis of the diagnostic modality.
Results Modality
True positive F
Mammography 9 5
Ultrasonography 15 3
Magnetic imaging spectroscopy 18 1In our study mammography showed low sensitivity and
speciﬁcity for detecting cancer recurrence (47.3% and 28.2%,
respectively) this might be because of post operative ﬁbrosis
and deformity or dense breasts in younger patients, while mic-
rocalciﬁcations made the diagnosis easier. This agreed with
Abdallah and colleagues (8) whom mentioned that the radio-
logic changes of the treated breast are highly variable and usu-
ally include skin thickening, increased density of the
ﬁbroglandular and suspensory ligaments or a mass or distor-
tion in the tumor bed due to scarring with overlap in the radio-
logic appearance between benign and malignant lesions.
Ultrasonography shows relative higher sensitivity and spec-
iﬁcity in detecting tumor recurrence (78.9% and 57.1%,
respectively) than mammography. It is easy and reliable but
in treated breasts fat necrosis and hypoechoic areas of ﬁbrosis
may have the similar appearance of malignancy. In addition
many studies mentioned that ultrasonography has limited
capability in excluding early malignancy (9).
Chen et al. (1) mentioned that the addition of single-voxel 1H
MRS could improve the diagnostic speciﬁcity of DCE-MRI.
Bartella et al. (10) found that the use of 1H MRS could signiﬁ-
cantly increase the positive predicting value (PPV) of biopsy
from 35% to 82% and obviate biopsy in 57% of the 40 lesions
with unknown histological features. Huang et al. (11) also
showed that the addition of 1H MRS to a conventional MRI
protocol increased the speciﬁcity from 62.5% to 87.5%. In our
study 1H MRS was a sensitive method to differentiate tumor
recurrence at the prior surgery site after conservative surgery
and radiation therapywith sensitivity of 94.7%andpositive pre-
dictive value of 94.7%. O’Flynn and De Souza (12) mentioned
that several studies have shown that choline concentration
(Cho) can be used as a marker of malignancy, and when com-
bined with DCE-MRI, increases the speciﬁcity of breast MRI.
Yeung et al. (13) mentioned that all cases of the special subtypes
of invasive cancer, including two cases of mucinous carcinoma,
two cases of medullary carcinoma, and one case of inﬁltrating
lobular carcinoma,were positive for choline at 1HMRspectros-ular carcinoma (n= 2), medullary carcinoma (n= 2) DCIS (n= 1)
4), post surgical extensive ﬁbrosis (n= 2), focal mastitis (n= 1)
alse positive True negative False negative
2 10
4 4
6 1
Fig. 1 DCE-MRI shows speculated enhanced soft tissue mass in women with previous BCT for IDC. MRS curve shows positive choline
with high peak at 3.2 ppm. Histopathology report was recurrent IDC (true positive case).
Fig. 2 DCE-MRI shows heterogeneous enhancement of a non-mass like lesion in a women with previous BCT for IDC. MRS shows
positive choline at 3.2 ppm. Histopathology revealed focal mastitis (false positive).
Fig. 3 DCE-MRI shows a fairly deﬁned nonhomogenously enhanced focal soft tissue lesion in a women with previous BCT for small
DCIS. MRS shows negative curve for choline. Histopathology reported recurrent DCIS (false-negative case).
22 E.M. Khattab et al.copy and this agreed with our study in whichMRS was positive
for choline in two cases of inﬁltrating lobular carcinoma and
two case ofmedullary carcinoma.Although 1HMRShas shown
promising results for evaluating breast cancer, a number of
false-negative ﬁndings have been reported with failure to detectcholine in some breast cancers (14). This might be related to var-
ious conditions such as too small or less aggressive tumors.
Other problems included patient motion, or contaminated tu-
mor tissue by inﬂammatory cells, ﬁbroglandular or fatty tissues
(14). In this study one casewas false negativewith absent choline
Fig. 4 DCE-MRI shows heterogeneous non-mass like enhancement in a women with previous lumpectomy for DCIS. MRS shows
absent choline with negative curve. Histopathology showed post operative ﬁbrosis (true positive case).
Fig. 5 DCE-MRI shows homogenous strong enhancement of axillary lymph node more than 1 cm in diameter. MRS curve is positive
for choline. Histopathology revealed malignant lymph node (true positive case).
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noma in situ and this result is agreed with the study done by
Chen et al. (1) in which ductal carcinoma in situ (DCI) and
IDC with an extensive in situ components were likely to be neg-
ative for choline at 1H MRS. This false-negative case reduced
our negative predictive value to 85.7%, also in the study done
by Tozaki (2), he mentioned the same results that DCI reduced
the sensitivity and speciﬁcity of his study and this ismight be due
to variability morphological pattern of DCI on MR imaging.
1H MR spectroscopy is a feasible technique that is capable of
depicting choline in metastatic axillary lymph nodes (14). In
our study four patients showed enlarged axillary lymph nodes
MRS successfully detected choline in all the four cases; however,
all these lymph nodes were larger than 1 cm and this might be a
second limitation of MRS that small subcentimeters lymph
nodes may be inaccurately evaluated by MRS examinations
especially at MR system that operates at 1.5 T. However, in
the near future with the introduction of clinical systems that
operate at 3.0 T and the development of better coils, it will be
interesting to see whether smaller breast lesions and lymph
nodes can be studied by using 1H MR spectroscopy (14).
5. Conclusion
1H MRS has a promising role in evaluating the conservatively
treated breasts with a suspected tumor recurrence, combina-
tion between DCE-MRI and MRS will be of great value in dif-ferentiating local recurrence from other post operative sequels
as well as detecting metastatic nodes in patients with recurrent
breast cancer. While one of its limitations is a failure to detect
choline in noninvasive cancers such as DCIS.References
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